Upregulation of TCF21 inhibits migration of adrenocortical carcinoma cells
- PMID: 35201460
- PMCID: PMC8777580
- DOI: 10.1007/s12672-021-00417-6
Upregulation of TCF21 inhibits migration of adrenocortical carcinoma cells
Abstract
Background: Adrenocortical carcinomas (ACC) are rare and aggressive cancer. Our previous study has revealed that the transcription factor 21, TCF21, is downregulated in ACC and regulates steroidogenic factor 1 (SF-1) binding to the SF-1 E-box promoter. In addition, it could be found that TCF21 is a predictor of overall survival (OS) in adult carcinomas.
Methods: In this study, it was investigated the correlation between TCF21 expression and the promoter methylation status in adrenocortical tumor cells, carcinomas and adenoma. The biological function and potential molecular mechanism of TCF21 restoration in migration and invasion of ACC cells was examined.
Results: We could be demonstrated a negative correlation between the level of TCF21 expression and methylation of its promoter in adenoma and carcinoma cells indicating the epigenetic control of TCF21 expression. It was also demonstrated that the expression of TCF21 inhibits migration and invasion in the ACC cell line, H295R cells, using plasmid transfection to express TCF21. Furthermore, it could be investigated the TCF21 function as tumor suppressor probably through Kisspeptin 1 (KISS-1) expression and epithelial-mesenchymal transition (EMT) reversion, as well as the modulation of several metalloproteinases in ACC cells.
Conclusions: Our results suggest that enhancement of TCF21 expression levels may be a potential strategy to revert invasive abilities in adrenocortical carcinomas.
Keywords: Adrenocortical carcinoma cells; Matrix metalloproteinases; Methylation; Migration; TCF21.
© 2021. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures










Similar articles
-
N-type calcium channel v2.2 is a target of TCF21 in adrenocortical carcinomas.Neoplasma. 2022 Jul;69(4):899-908. doi: 10.4149/neo_2022_220106N25. Epub 2022 May 23. Neoplasma. 2022. PMID: 35603952
-
Expression of Transcription Factor 21 (TCF21) and Upregulation Its Level Inhibits Invasion and Metastasis in Esophageal Squamous Cell Carcinoma.Med Sci Monit. 2018 Jun 17;24:4128-4136. doi: 10.12659/MSM.909138. Med Sci Monit. 2018. PMID: 29909422 Free PMC article.
-
POD-1 binding to the E-box sequence inhibits SF-1 and StAR expression in human adrenocortical tumor cells.Mol Cell Endocrinol. 2013 May 22;371(1-2):140-7. doi: 10.1016/j.mce.2012.12.029. Epub 2013 Jan 9. Mol Cell Endocrinol. 2013. PMID: 23313103 Free PMC article.
-
Multiple biological functions of transcription factor 21 in the development of various cancers.Onco Targets Ther. 2018 Jun 19;11:3533-3539. doi: 10.2147/OTT.S164033. eCollection 2018. Onco Targets Ther. 2018. PMID: 29950858 Free PMC article. Review.
-
TCF21: a critical transcription factor in health and cancer.J Mol Med (Berl). 2020 Aug;98(8):1055-1068. doi: 10.1007/s00109-020-01934-7. Epub 2020 Jun 15. J Mol Med (Berl). 2020. PMID: 32542449 Review.
References
-
- Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1–G34. doi: 10.1530/EJE-16-0467. - DOI - PubMed
-
- Fassnacht M, Dekkers O, Tobias E, Baudin E, Berruti A, de Krijger R, Haak H, Mihai R, Assie G, Terzolo M. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Pract Guidel Eur J Endocrinol. 2018;179(4):G1–G46. doi: 10.1530/EJE-18-0608. - DOI - PubMed
LinkOut - more resources
Full Text Sources